Big Pharma (Drug Companies) Control Psychiatry

Ever wonder how much control the drug industry exerts on psychiatry? Here's a good one:

As reported in the San Jose Mercury News, Juy 10, 2006:

Dr. Alan F. Schatzberg, Stanford's long-time chair of the department of psychiatry, has reported financial interests with a number of companies that make psychiatric pills and devices, including:

Abbott Laboratories Inc.: consultant or scientific advisory board
Bristol-Myers Squibb: consultant or scientific advisory board; grant support
Corcept Therapeutics: scientific advisory board chairman; board of directors; stock
Elan Pharmaceuticals: stock or options
Eli Lilly and Co.: consultant or scientific advisory board; grant support
Forest Laboratories: consultant or scientific advisory board
GlaxoSmithKline: consultant or scientific advisory board; grant support
Janssen Pharmaceutica Products: consultant or scientific advisory board
Merck: stock or options
Neuronetics: consultant or scientific advisory board
Organon Pharmaceuticals: consultant or scientific advisory board
Pathway Diagnostics: stock or options
Pfizer: consultant or scientific advisory board; stock or options
Sanofi-Aventis: consultant or scientific advisory board
Somaxon Pharmaceuticals: consultant or scientific advisory board; stock or options
Somerset Pharmaceuticals: consultant or scientific advisory board; grant support
Wyeth Pharmaceuticals: consultant or scientific advisory board; grant support

Source: American Psychiatric Association; Corcept Therapeutics